Document Detail


Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies.
MedLine Citation:
PMID:  16709307     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients with neurogenic bladder represent a small fraction of the total overactive bladder population. As a consequence, development of new therapies in this area has largely focused on idiopathic urinary incontinence. The absence of data for patients with neurological disease has far-reaching implications, affecting reimbursement and physicians' willingness to prescribe therapies, and limiting access of potential valuable treatments to patients whose lives are significantly impaired by inadequately managed bladder symptoms. SCOPE: The range of new therapies is increasing. Although many reviews of the overall safety, efficacy and mode of action of such treatments are available, there is limited information on how these treatments will best be used in clinical practice. We considered the current benefits and limitations of the various new licensed and unlicensed therapies and what role each would have in the future management of neurogenic urinary incontinence. CONCLUSIONS: A wide range of new treatments have been investigated for the management of overactive bladder; few, however, have been evaluated extensively in neurogenic urinary incontinence. Further studies are required to determine the optimal dosing regimes and formulations for individual sub-populations of neurogenic bladder patients and to determine the cost-effectiveness of these interventions. With the current experience available, two treatment algorithms for a subset of patients with neurological disease have also been proposed, which suggest at which stage of management and in which patients individual therapies for neurogenic urinary incontinence could be used.
Authors:
Pierre Denys; Jacques Corcos; Karel Everaert; Emmanuel Chartier-Kastler; Clare Fowler; Vinay Kalsi; Victor Nitti; Heinrich Schulte-Baukloh; Brigitte Schurch
Related Documents :
2664227 - Sonographic evaluation and conservative management of newborns with myelomeningocele an...
7120547 - Urinary diversion via a continent ileal reservoir: clinical results in 12 patients.
19013597 - Use of ileum as ureteral replacement in urological reconstruction.
16493217 - Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alph...
7042357 - Double-blind multicentre, between patients comparison of indoprofen and indomethacin in...
9314397 - Total hip arthroplasty for congenital dysplasia or dislocation of the hip. survivorship...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current medical research and opinion     Volume:  22     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-19     Completed Date:  2006-09-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  851-60     Citation Subset:  IM    
Affiliation:
Hôpital Raymond Poincaré, Garches, France. pierre.denys@rcp.ap-hop-paris.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms
Botulinum Toxin Type A / pharmacology,  therapeutic use
Cannabinoids / pharmacology,  therapeutic use
Capsaicin / pharmacology,  therapeutic use
Cholinergic Antagonists / pharmacology,  therapeutic use
Diterpenes / pharmacology,  therapeutic use
Humans
Muscarinic Antagonists / pharmacology,  therapeutic use
Treatment Outcome
Urinary Bladder, Neurogenic / complications,  drug therapy*
Urinary Incontinence / drug therapy*,  etiology
Chemical
Reg. No./Substance:
0/Botulinum Toxin Type A; 0/Cannabinoids; 0/Cholinergic Antagonists; 0/Diterpenes; 0/Muscarinic Antagonists; 404-86-4/Capsaicin; 57444-62-9/resiniferatoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Next Document:  Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 di...